NEW YORK, August 10, 2016 /PRNewswire/ --
Despite regulatory concerns, M&A activities are expected to continue pushing some Biotech stocks to new highs. The industry belongs in the Healthcare sector which was up by 0.6% on Tuesday, August 09, 2016. Stock-Callers.com takes a look at today's featured companies and see how they fared at the close: bluebird bio Inc. (NASDAQ: BLUE), Sage Therapeutics Inc. (NASDAQ: SAGE), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Alder Biopharmaceuticals Inc. (NASDAQ: ALDR). Register now and get full and free access to our downloadable research reports on these stocks at:
On Tuesday, Cambridge, Massachusetts headquartered bluebird bio Inc.'s stock recorded a trading volume of 536,426 shares and ended the session 1.35% higher at $56.21. The Company's shares have surged 15.49% in the last one month and 37.77% in the previous three months. The stock is trading 20.02% above its 50-day moving average and 5.75% above its 200-day moving average. Moreover, shares of bluebird bio, which focuses on developing transformative gene therapies for severe genetic and rare diseases, have a Relative Strength Index (RSI) of 59.35.
On August 3rd, 2016, the company reported that collaboration revenue was $1.6 million for the Q2 2016 compared to $4.9 million for Q2 2015. The company's net loss was $58.8 million for Q2 2016 compared to $51.8 million for Q2 2015.
On August 04th, 2016, research firm Maxim Group reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $105 a share to $85 a share. Access our complete research report on BLUE for free at:
Cambridge, Massachusetts headquartered Sage Therapeutics Inc.'s stock closed the day 13.19% lower at $36.86. A total volume of 2.40 million shares was traded, which was above their three months average volume of 863,130 shares. The Company's shares have advanced 9.54% in the past month and 6.50% over the previous three months. The stock is trading 2.29% above its 50-day moving average. Additionally, shares of Sage Therapeutics, which develops and commercializes novel medicines to treat central nervous system disorders, have an RSI of 39.94.
On August 9th, 2016, Sage Therapeutics reported net loss of $34.7 million for Q2 2016 compared to net loss of $25.0 million for Q2 2015. The company's cash, cash equivalents, and marketable securities were $272.3 million as of June 30th, 2016, compared to $186.8 million at December 31st, 2015. The complimentary research report on SAGE can be downloaded at:
Shares in Novato, California headquartered Ultragenyx Pharmaceutical Inc. recorded a trading volume of 456,142 shares. The stock ended yesterday's trading session 0.58% lower at $64.97. The Company's shares have advanced 22.86% in the past month and 2.23% in the previous three months. The stock is trading above its 50-day moving average by 11.23%. Furthermore, shares of Ultragenyx Pharmaceutical, which focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the US, have an RSI of 63.17.
On August 08th, 2016, Ultragenyx reported a net loss of $56.9 million, or $1.46 per share (basic and diluted), for Q2 2016 compared to a net loss of $29.8 million, or $0.83 per share (basic and diluted) for Q2 2015. The company's total operating expenses for Q2 2016 were $58.1 million compared to $30.1 million for Q2 2015. Register for free on Stock-Callers.com and get access to the latest PDF format report on RARE at:
Bothell, Washington headquartered Alder Biopharmaceuticals Inc.'s stock finished Tuesday's session 0.92% higher at $30.70 and with a total volume of 219,333 shares traded. The Company's shares have advanced 14.21% in the last one month and 17.53% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 9.79% and 9.92%, respectively. Additionally, shares of Alder Biopharmaceuticals, which discovers, develops, and commercializes therapeutic antibodies in the US and Australia, have an RSI of 57.14.
On July 25th, 2016, Alder BioPharmaceuticals announced top-line 24-week data demonstrating persistent migraine prevention in a Phase 2b clinical trial evaluating ALD403 in patients with chronic migraine. The company noted that the 24-week data confirm and extend the 12-week data reported previously, including the 75% reduction in migraine days over 12 weeks and the mean reduction in migraine days from baseline, the primary efficacy and secondary endpoints, respectively. In March 2016, Alder reported that the Phase 2b study met both the primary efficacy endpoint, a 75% reduction in migraine days over 12 weeks, and the secondary efficacy endpoint of mean reduction in migraine days from baseline. Download your free research report on ALDR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA